GINS2

Across TCGA pan-cancer cohorts, GINS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GINS2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GINS2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GINS2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, OV, and CCRCC are the cancer types where GINS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	1.000	0.563	<.001	37	view →
OV	DFS	Tertile	All	0.819	1.000	.031	12	view →
CCRCC	DFS	Median	III,IV	0.104	0.878	.010	7	view →
LUAD	DFS	Tertile	III,IV	0.971	0.560	.049	3	view →
PDAC	OS	Median	All	0.778	0.996	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GINS2–LSCC (OS)

Open the LSCC breakdown →